Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1636 1654 1656 1658 1674 1676 1764
This examiner grants 66% of resolved cases
Lianko G. Garyu is an examiner in Art Unit 1636 of Tech Center 1700 with 583 resolved cases. The allowance rate is 66.0 percent. The median days to allowance of 1020 indicates the time required for applications to reach a grant. This 1020-day figure is a data point for practitioners to use when managing expectations regarding the timeline of prosecution.
The interview lift is 45.4 percent. This figure is an increase when compared to the 66.0 percent allowance rate, indicating that direct communication is an effective tool. For the 583 cases resolved, the data suggests that Garyu is responsive to verbal advocacy. Practitioners should prioritize interviews to capitalize on the 45.4 percent lift and potentially resolve issues during the 1020-day median pendency. The 66.0 percent allowance rate provides a foundation for applications in Art Unit 1636.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17636839 | UBE3A FOR THE TREATMENT OF ANGELMAN SYNDROME | Final Rejection | The Regents of the University of California |
| 18259637 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | Non-Final OA | NEW YORK UNIVERSITY |
| 18461041 | Heteromultivalent Nucleic Acid Scaffolds and Uses Thereof | Non-Final OA | George Mason University |
| 18618666 | COMPOSITION FOR LOWERING BLOOD SUGAR CONTAINING GREEN TEA PEPTIDE COMPOSITION | Non-Final OA | AMOREPACIFIC CORPORATION |
| 18196168 | C-Peptide as a Therapy for Patients with Diabetes | Non-Final OA | University of Cincinnati |
| 18712828 | STABLE INJECTABLE COMPOSITIONS OF GLP-2 PEPTIDE | Non-Final OA | ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy